Literature DB >> 31292137

Reproductive and Lifestyle Factors and Circulating sRANKL and OPG Concentrations in Women: Results from the EPIC Cohort.

Danja Sarink1, Jiaxi Yang2, Theron Johnson1, Jenny Chang-Claude1,3, Kim Overvad4, Anja Olsen5, Anne Tjønneland5,6, Agnès Fournier7,8, Francesca Romana Mancini7,8, Marina Kvaskoff7,8, Heiner Boeing9, Antonia Trichopoulou10, Anna Karakatsani10,11, Elissavet Valanou10, Claudia Agnoli12, Carlotta Sacerdote13, Giovanna Masala14, Amalia Mattiello15, Rosario Tumino16, Carla H Van Gils17, Guri Skeie18,19, Inger Torhild Gram18, Elisabete Weiderpass20, Leila Lujan-Barroso21, Dafina Petrova22,23, Carmen Santiuste23,24, J Ramón Quirós25, Aurelio Barricarte23,26,27, Pilar Amiano23,28, Ruth C Travis29, Marc Gunter20, Laure Dossus20, Sofia Christakoudi30,31, Rudolf Kaaks1, Renée Turzanski Fortner32.   

Abstract

BACKGROUND: Except for a documented increase in osteoprotegerin (OPG) concentrations with older age, data on determinants of soluble Receptor Activator of Nuclear Factor κB (sRANKL) and OPG concentrations in women are limited. We evaluated reproductive and lifestyle factors as potential sources of variation in circulating sRANKL and OPG concentrations in pre- and postmenopausal women.
METHODS: This study includes 2,016 controls [n = 1,552 (76%) postmenopausal, n = 757 (38%) using postmenopausal hormone therapy (PMH)] from a breast cancer case-control study nested in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Serum sRANKL was measured using an ELISA and serum OPG using an electrochemiluminescent assay. Generalized linear models were used to evaluate associations between these analytes and reproductive and lifestyle factors.
RESULTS: Older age at blood collection was associated with lower sRANKL concentrations in postmenopausal women (P trend ≤ 0.03) and higher OPG concentrations in all women (P trend ≤ 0.01). Longer duration of oral contraceptive use among premenopausal women and postmenopausal PMH users was associated with higher OPG (P trend ≤ 0.04). In postmenopausal non-PMH users, sRANKL concentrations were lower with longer duration of oral contraceptive use and current (vs. never) smoking (P ≤ 0.01). sRANKL concentrations were higher among women with higher BMI (P trend ≤ 0.01). The evaluated factors accounted for 12% of the variation in sRANKL concentrations and 21% of the variation in OPG concentrations.
CONCLUSIONS: Circulating sRANKL and OPG concentrations are minimally impacted by hormone-related factors in pre- and postmenopausal women. IMPACT: This study suggests circulating concentrations of sRANKL and OPG are unlikely to be strongly modified by hormone-related reproductive and lifestyle factors. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31292137     DOI: 10.1158/1055-9965.EPI-19-0241

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  4 in total

1.  Premenopausal Plasma Osteoprotegerin and Breast Cancer Risk: A Case-Control Analysis Nested within the Nurses' Health Study II.

Authors:  Rulla M Tamimi; A Heather Eliassen; Joanne Kotsopoulos; Emma E McGee; Susana Lozano-Esparza; Judy E Garber; Jennifer Ligibel; Laura C Collins; Kornelia Polyak; Myles Brown; Steven Narod
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-04-10       Impact factor: 4.254

2.  Local Production of Osteoprotegerin by Osteoblasts Suppresses Bone Resorption.

Authors:  Keisha M Cawley; Nancy Cecile Bustamante-Gomez; Anveshi G Guha; Ryan S MacLeod; Jinhu Xiong; Igor Gubrij; Yu Liu; Robin Mulkey; Michela Palmieri; Jeff D Thostenson; Joseph J Goellner; Charles A O'Brien
Journal:  Cell Rep       Date:  2020-09-08       Impact factor: 9.423

Review 3.  Delineating the role of osteoprotegerin as a marker of breast cancer risk among women with a BRCA1 mutation.

Authors:  Sarah Sohyun Park; Aleksandra Uzelac; Joanne Kotsopoulos
Journal:  Hered Cancer Clin Pract       Date:  2022-04-13       Impact factor: 2.857

4.  Sex Differences in Proatherogenic Cytokine Levels.

Authors:  Stella Bernardi; Barbara Toffoli; Federica Tonon; Morena Francica; Elena Campagnolo; Tommaso Ferretti; Sarah Comar; Fabiola Giudici; Elisabetta Stenner; Bruno Fabris
Journal:  Int J Mol Sci       Date:  2020-05-29       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.